The strategic metabolic health partner for your clients

Reverse chronic metabolic disease and reduce your clients' costs with proven, multi-year ROI

What sets Virta apart

Proof you can defend

Virta gives employers and health plans more than participation metrics or engagement claims. Our model is backed by clinical outcomes, economic evidence, and real-world results that make the value clear. All while putting 100% of our fees at risk*.

Flexible by design, with or without GLP-1s

Clinical outcomes are maintained with any of our coverage or fulfillment pathways. Whether your clients choose to cover GLP-1s, restrict them, or exclude them, Virta integrates seamlessly into their benefit design.

Sustainable changes improve health and reduce costs

Virta makes behavior change more achievable by helping members understand what works for their body. Through provider-led care, coaching, personalized nutrition, and real-time feedback, members get support they can use in everyday life.

Why partner with Virta

Proven results, backed by 10+ years of experience, outcomes cited by the ADA, and a growing base of 30+ peer reviewed publications.

Medication reduction

 59%
Sustained medication reduction alongside improved metabolic health.1

Reduction in heart attack, stroke, and death

 56%
Lower incidence of serious downstream cardiometabolic events.2

ROI

 2.75x
based on real world outcomes3

Overcoming objections

Easy path to partnership

Simple contracting

Direct or via 45+ health plan, PBM, and vendor partners

Flexible implementation

Go live anytime in as little as 90 days

Supported launch

Dedicated marketing support drives adoption

Ongoing touchpoints

Tailored engagement strategy drives member success

CFO approved

Immediate savings

In-year savings

Shared risk

100% of fees at risk*

Flexible billing

Via claims or invoicing

Transparent results

Actuary grade savings estimate and clear reporting

Designed to support all aspects of your clients’ metabolic strategy

Flexible, high-impact clinical solutions for your clients’ most complex health challenges.

GLP-1 Cost

Support before, during, and after use

Virta supports your client’s objective whether it’s nutrition support before Rx, reducing medication dependency, or sustaining results post-Rx

Type 2 Diabetes Claim Spend

Reduce cost burden

Go beyond chronic disease management to improve glycemic control, safely reduce medication dependency, and reverse type 2 diabetes

Metabolic Disease Progression

Provide members a path forward

Virta delivers clinically meaningful weight loss, reversing metabolic disease progression with and without the use of GLP-1s

Vendor Fatigue

Consolidate metabolic health support

Use one clinical model to support members across obesity, diabetes, and related cardiometabolic risk

Frequently asked questions

Which clients and populations are a good fit for Virta?
How does Virta fit into my clients’ existing benefits ecosystem?
How does Virta help my clients manage GLP-1 costs and utilization?
What kind of experience can my clients’ employees expect from Virta?
How does Virta support consultants throughout the evaluation and recommendation process?
How does Virta demonstrate ROI for my clients?

See what Virta can do for your clients

Fill out this quick form and our team will create an ROI analysis to review with you in the next 5 business days.

Not ready to request an ROI? Reach out to consultants@virtahealth.com with any questions.

* 100% fees at risk in first year for employer partners
Citations and Footnotes
  1. Hallberg SJ et al. Diabetes Ther. 2018; 9(2): 583-612. Outcomes among one year completers (83% retention in Virta Treatment; 90% retention in Standard Care). Rx refers to the volume of diabetes prescriptions at one year (which excludes metformin) compared to baseline and multiple insulins prescribed to a patient were counted as one Rx.
  2. Roberts CGP, Shanmugam PV, Athinarayanan SJ, Wolfberg AJ, Raskin S, Lopez-Jimenez F. Cardiovascular Outcomes Among Adults with Type 2 Diabetes or Obesity Receiving Carbohydrate-Reduced Nutrition via Telemedicine: A Retrospective Claims-Based Cohort Study. Cardiol Ther. 2026 Oct 2. doi: 10.1007/s40119-026-00478-0.
  3. Source: Milliman Antidiabetic Med Trend Study,AON Medical Trends, US - Shows 8.8%, and Virta Health Actuarial analysis, details available upon request.